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Background
Gastrointestinal stromal tumors (GISTs) constitute the
most common non epithelial neoplasm that occur
within the gastrointestinal tract with a world wide
annual incidence of 8-14/million. They are usually
located in the upper gastrointestinal tract particularly in
the stomach (60%), in the small bowel (30%), esophagus
(5%) and rectum (5%). Gist(s) origin from sporadic
mutations within the tyrosine-kinase receptors of the
interstitial Cajal cells. The clinical presentation of Gist
(s) is quite heterogeneous [1]. The most common asso-
ciated symptoms are abdominal pain, bleeding, gastro-
enteric outlet obstruction. Modern cross-sectional
imaging studies include TC and/or magnetic resonance
imaging in combination with upper endoscopy. Upper
endoscopy with ultrasonography (EUS) is an useful tool
to pick tissue for diagnosis for cytology (FNA) or tru-
cut biopsy. In addition EUS can show the depth of
penetration through the layers of the gastro-enteric wall
and origin of these neoplasm .
Routinary biopsies increase the risk of tumor spillage
or hemorrhage with consequent higher rate of recur-
rence or disseminated sarcomatosis therefore only selec-
tive biopsies are recommended [2].
Complete surgical resection is the only curative therapy
of Gist without metastasis. Surgery of large Gists may
result technically difficult. However debulking before
molecular therapy or reducing the size with neoadjuvant
therapy by imatinib can give longer survival and better
results [3].
In this study we report our experience on surgical
treatment of 16 patients with localized gastrointestinal
stromal tumors.
Methods
From 2003 to 2011, 16 cases of gastrointestinal stromal
tumors underwent to surgery in the Department of Gas-
trointestinal Surgery of Naples University “Federico II”.
There were 7 males and 9 females with a mean age of
63.2 years (range 53-84 years). All the patients under-
went surgery for localyzed Gist.
Diagnosis was based on histo-pathological appearance
and was confirmed by positive immunohistochemical
staining for c-kit protein CD 117, CD34, SMA, S100
were also performed.
All patients underwent surgical resection. On the basis
of size of the primary tumor, mitotic index an Fletcher’s
criteria, the tumors were classified as very low, low,
intermediate and high risk 4.
Survival and relapse rate were considered. For survival
analysis was used the Log-rank test. Statistical signifi-
cance of frequencies was performed with c square test
and T test for means comparison.
Results
From June 2003 to November 2011, 16 patients were
diagnosed with Gist 6 patients were referred after diag-
nosis defined elsewhere. 8 patients were symptomatic
and 4 of them presented with abdominal mass, 1 had as
first symptom gastrointestinal bleeding, 1 presented with
gut occlusion, 2 had appetite and weigth loss.
The organs affected were primary the stomach in 9
cases and small bowel in 7. The NIH class of risk at the
pathological evaluation after surgery was high 4/16
(25%), intermediate 2/16 (12.5%), low 7/16 (44%), very
low 3/16 (9%). On histopathology 98% of cases were
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positive for CD 117 immunohistochemistry, CD 34 was
81%, SMA 45%, S100 28%.
Of 16 who underwent surgical treatment, 13 (81%)
underwent complete resection (R0), 2 had R1 resection, in
these latter patients, tumor was located in small bowel.
Four of the patients who had a complete resection later
developed local recurrence. Thyrosine kinase inhibitor
therapy was given to patients with residual disease R1
resection, in case of relapse after primary surgical resec-
tion. Of 6 patients who received tyrosine kinase inhibitor
therapy (400 mg/day), 4 had no progression disease 1 had
progressive disease and 1 had no complete response.
We analyzed disease free survival at five years and
relapse rate in all patients. Twelve patients belonging to
low and intermediate risk group had disease free survi-
val of 90%.
In high risk group patients, disease free survival was
50% at five years. In four patient in the high risk group,
we observe 2 relapses of disease with massive progression
of disease due to liver metastatic out peritoneal metasta-
sis. These patients died 26 months and 34 months after
surgical operation. Low-risk patients did not receive any
treatment and were all disease free at the follow-up. One
of two intermediate- risk patients had recurrence in the
peritoneum 32 months after surgery and imatinib was
increased to 600 mg/day.
Conclusions
This study consisted of heterogeneous groups of patients.
The mean age of the patients was 63.2. The most common
site of Gist was the stomach in 9 cases and the small
bowel in 7 cases. The mainstay treatment of Gist is surgi-
cal excision. The global five year disease free survival was
81%. When complete resection is not possible, target ther-
apy with tyrosine-kinase is the choice treatment. In our
study only few patients belonged to the high risk group
(4/16). We found that the failure cases occurred in the ori-
ginal high and intermediate risk category. This result may
suggest an essential role of postoperative adjuvant treat-
ment in the high risk patients. De Matteo 5 suggested
adjuvant imatinib treatment may improve disease free sur-
vival after surgical resection of primary gastrointestinal
stromal tumor. In terms of survival a good outcome is
expected when a complete tumor excision is obtained.
Moreover patient who were in the low risk group, had
more possibility to have a complete tumor removal and
survival probability is more than 90%. In conclusion the
advent of new molecular markers has led to improve local
control and improve disease-free survival. Prognosis is
mainly influenced by tumor respectability risk-categoriza-
tion and response to tyrosine kinase treatment. However,
large, randomized prospective trials are still needed to
address the best therapeutic modalities and improve
survival.
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